Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegylated Interferon Alpha for Rhinovirus in Hypogammaglobulinemia
NCT02661477Phase 2Unknown
- Sponsor
- Turku University Hospital
- Start
- May 2016
- Primary completion
- May 2018
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of peginterferon alfa-2a in rhinovirus infection (2 arms), sponsored by Turku University Hospital. Primary endpoints: Duration of respiratory symptoms at 2 months, Eradication of rhinovirus from nasal secretion at 2 months and 1 more. Status: unknown.
02
Drugs
peginterferon alfa-2a
03
Conditions
rhinovirus infection
Beyond the preview
Go deeper on NCT02661477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02661477.